WPRIM Management System> DCMS> Acta Pharmaceutica Sinica> 2013> 48> 10

Volume: 48 Issue: 10

1. Bufo gargarizans mcl-1 cloning and its prokaryotic recombinant protein expression. Page:1624—1628
2. Construction of Saccharomyces cerevisiae whole-cell biocatalyst system for conversion miltiradiene. Page:1618—1623
3. Analysis and comparison of intestinal absorption of components of Gegenqinlian decoction in different combinations based on pharmacokinetic parameters. Page:1611—1617
4. Preparation of self-microemulsion drug delivery system of the mixture of paeonol and borneol based on Xingbi Fang. Page:1602—1610
5. Between Hengshanhuangqi and Chuanhuangqi based on metabolomics and ITS2 sequences. Page:1595—1601
6. Effects of lamivudine on growth of intestinal characteristic bacteria by microcalorimetry in vitro. Page:1590—1594
7. Sample pretreatment methods of pesticide residues in Panax notoginseng of Chinese traditional medicine. Page:1585—1589
8. Synthesis and immunosuppressive effects of novel phthalazine ketone derivatives. Page:1579—1584
9. Design, synthesis and PPAR agonist activities of novel L-tyrosine derivatives containing phenoxyacetyl moiety. Page:1570—1578
10. Optimization of the preparation process for fusion protein Fv-LDP that composes lidamycin apoprotein and single-chain Fv antibody directed against type IV collagenase. Page:1563—1569
11. Therapeutic effect of a natural squamosamide derivative FLZ on Parkinson's disease model mice induced by LPS plus MPTP. Page:1557—1562
12. Inhibitory effects of fluvastatin on activation of THP-1 cells induced by anti-beta2GPI/beta2GPI complex. Page:1550—1556
13. Construction of anti-VEGFR-2 IgG1 like human antibody and its expression in CHO-k cells. Page:1544—1549
14. Research advances in brain-targeted nanoscale drug delivery system. Page:1532—1543
15. Lead compound optimization strategy (1)--changing metabolic pathways and optimizing metabolism stability. Page:1521—1531
16. Advances in the research of anti-CD20 therapeutic monoclonal antibodies. Page:1515—1520
17. Advances in the research of anti-CD20 therapeutic monoclonal antibodies. Page:1515—20
18. Lead compound optimization strategy (1)--changing metabolic pathways and optimizing metabolism stability. Page:1521—31
19. Research advances in brain-targeted nanoscale drug delivery system. Page:1532—43
20. Construction of anti-VEGFR-2 IgG1 like human antibody and its expression in CHO-k cells. Page:1544—9
21. Inhibitory effects of fluvastatin on activation of THP-1 cells induced by anti-beta2GPI/beta2GPI complex. Page:1550—6
22. Therapeutic effect of a natural squamosamide derivative FLZ on Parkinson's disease model mice induced by LPS plus MPTP. Page:1557—62
23. Optimization of the preparation process for fusion protein Fv-LDP that composes lidamycin apoprotein and single-chain Fv antibody directed against type IV collagenase. Page:1563—9
24. Design, synthesis and PPAR agonist activities of novel L-tyrosine derivatives containing phenoxyacetyl moiety. Page:1570—8
25. Synthesis and immunosuppressive effects of novel phthalazine ketone derivatives. Page:1579—84
26. Sample pretreatment methods of pesticide residues in Panax notoginseng of Chinese traditional medicine. Page:1585—9
27. Effects of lamivudine on growth of intestinal characteristic bacteria by microcalorimetry in vitro. Page:1590—4
28. Between Hengshanhuangqi and Chuanhuangqi based on metabolomics and ITS2 sequences. Page:1595—601
29. Preparation of self-microemulsion drug delivery system of the mixture of paeonol and borneol based on Xingbi Fang. Page:1602—10
30. Analysis and comparison of intestinal absorption of components of Gegenqinlian decoction in different combinations based on pharmacokinetic parameters. Page:1611—7
31. Construction of Saccharomyces cerevisiae whole-cell biocatalyst system for conversion miltiradiene. Page:1618—23
32. Bufo gargarizans mcl-1 cloning and its prokaryotic recombinant protein expression. Page:1624—8

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.